Sanofi, GSK Say Their Covid Booster Works Better Against Omicron

Sanofi and GSK Plc, the pharma giants that stumbled in the race to develop a Covid-19 shot, said their experimental booster vaccine delivers a more powerful immune response against coronavirus variants than their competitors’.

The shot raised antibody levels in adults already inoculated with messenger RNA vaccines more than the additional doses from Pfizer Inc. and BioNTech SE, and demonstrated potential to protect against variants including omicron, GSK and Sanofi said in a statement Monday, citing data from two trials.

The “next-generation booster” includes GSK’s pandemic adjuvant -- a substance that enhances the immune response to vaccines ...